Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Oxyrane General Information
Oxyrane is developing enhanced enzyme replacement therapies with superior pharmacodynamics. Their lead program for Gaucher Disease has demonstrated superior pharmacodynamic effects in disease animal models. They are also advancing a treatment for Pompe disease through preclinical stages.
Contact Information
Drug Pipeline
OXY-GAA
Phase 1/2Key Partnerships
Bioasis Technologies Inc.
Oxyrane Funding
No funding data available
To view Oxyrane's complete valuation and funding history, request access »